Reviewer’s report

Title: Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Version: 1 Date: 9 February 2014

Reviewer: Evangelos Rizos

Reviewer’s report:

This is a well written article by Sinclair et al on the differences of canagliflozin in older people.

Major comments:
1. Although the manuscript is very well written, there are some serious methodological issues. The authors have performed a pooled analysis of their data, instead of performing a meta-analysis of the 4 studies. A meta-analysis would help to address the issues of heterogeneity of the different studies, whereas the pooled analysis represents only a gathering and re-analysis of the data.

2. The choice of 65 years of age as a cut off is arbitrary. I understand that 65 years of age represents a common threshold for the definition of older people, but what about octogenarians or other age groups of older people? This could be addressed with an analysis taking age as a covariate.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

Speaker honoraria, consulting fees, clinical trials with: Novartis, Sanofi, Novo, AstraZeneca/BMS, MSD, Vianex, Boehringer Ing, Plus Pharmaceutical.

I have no competing interest in relation to the paper I am reviewing.